• The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. • Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FDA pilot program that speeds up regulatory review of medicines deemed critical for national security or public health. • The post Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA appeared first on MedCity News .

Article Summaries:

  • The FDA has declined to grant accelerated review status to Disc Medicine’s bitopertin, a treatment for erythropoietic protoporphyria, a rare blood disorder. Regulators requested additional data to confirm the drug’s clinical benefit before it can be approved. The decision surprised observers because bitopertin was among the first candidates selected for the FDA’s new pilot program that expedites review for drugs deemed critical to public health or national security. The move underscores the agency’s insistence on robust evidence even for therapies in high‑priority categories. The announcement was reported by MedCity News.

Sources: